Anti-CD3 monoclonal antibody 145-2C11

Drug Profile

Anti-CD3 monoclonal antibody 145-2C11

Alternative Names: 145-2C11; 145-2C11-IgG2a; 145-2C11-IgG3; 2C11; Anti-CD3 monoclonal antibody 2C11

Latest Information Update: 15 Jan 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bristol-Myers Squibb; PDL BioPharma; University of Cincinnati
  • Developer Bristol-Myers Squibb; PDL BioPharma
  • Class Monoclonal antibodies
  • Mechanism of Action Immunostimulants; Natural killer cell stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer; Transplant rejection

Most Recent Events

  • 02 Jul 1997 New profile for Cancer
  • 02 Jul 1997 Preclinical development for Cancer in USA (Unknown route)
  • 13 Feb 1996 A study has been added to the pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top